查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971858

基因静默市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、最终用户、组件、製程、模式、阶段划分

Gene Silencing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Process, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 488 Pages | 商品交期: 3-5个工作天内

价格
简介目录

基因静默市场预计将从2024年的46.6亿美元成长到2034年的113.1亿美元，复合年增长率约为9.3%。基因静默市场涵盖旨在抑制基因表现的技术和方法，例如RNA干扰和反义寡核苷酸。该市场支持遗传疾病和癌症的研究和治疗应用。在遗传疾病日益增多和生物技术进步的推动下，递送系统和特异性方面的创新至关重要。对个人化医疗和新型治疗方法的需求正在推动市场成长，并促进生物技术公司和学术机构之间的合作。

基因静默市场正经历强劲成长，这主要得益于基因研究和治疗应用领域的进步。 RNARNA干扰领域是市场的主要驱动力，其中小干扰RNA（siRNA）技术凭藉其精准的基因标靶化占据主导。反义寡核苷酸（ASO）紧随其后，这得益于其在各种条件下调控基因表现的多功能性。在RNA干扰领域，治疗应用子领域表现最为强劲，为遗传疾病和癌症的治疗方法提供了极具前景的方案。研究应用子领域位居第二，主要得益于基因组研究投入的不断增加。递送技术领域也发展迅猛，脂质奈米颗粒因其递送效率和安全性而成为基因静默剂的首选载体。递送系统的创新发展以及个人化医疗应用的不断拓展进一步推动了市场成长。生技公司与研究机构之间的策略联盟正在强化开发平臺，并为相关人员创造盈利的机会。

市场区隔
类型 短干扰RNA（siRNA）、微型RNA（miRNA）、短髮夹RNA（shRNA）、反义寡核苷酸（ASO）
产品 试剂、设备和试剂盒
服务 基因静默研究、客製合成、咨询
科技 RNA干扰（RNAi）、CRISPR-Cas9和反义技术
应用 药物发现与开发、功能基因体学、疾病诊断、治疗药物
最终用户 製药公司、生技公司、学术研究机构、受託研究机构
成分 载体、转染试剂及递送载体
过程 体外、体内
模式 直接的，间接的
步 药物发现、临床前研究、临床研究、商业化

市场概况：

基因静默市场正经历动态变化，主要产业参与者占据了相当大的市场。定价策略日趋激烈，反映出新参与企业和创新科技的涌入。近期产品推出引进了先进的基因静默技术，并增强了治疗应用和研究能力。这造成了竞争异常激烈的市场环境，尤其是在研究经费和生技投资充裕的地区。市场格局的特点是产品供应的持续演变，而这主要由技术进步和策略联盟所驱动。从竞争标竿分析的角度来看，产业领导企业正在大力投资研发以保持其优势。法规结构，尤其是在北美和欧洲，对塑造市场动态至关重要。这些法规确保了安全性和有效性，并影响产品核可时间和打入市场策略。专利法和智慧财产权进一步影响竞争格局，它们对于维持创新和保护专有技术至关重要。市场前景广阔，个人化医疗和RNA干扰技术预计将带来成长机会。

主要趋势和驱动因素：

基因静默市场正经历强劲成长，这主要得益于基因研究和生物技术的进步。一个关键趋势是RNA干扰（RNAi）技术在治疗研发中的应用日益广泛，为遗传性疾病和慢性疾病提供了标靶治疗方案。全球范围内这些疾病的日益流行进一步推动了这一趋势。另一个关键驱动因素是製药和生技公司不断增加的研发投入。这些投入旨在发现新型基因静默技术并拓展其治疗应用。值得注意的是，基因静默技术在农业生物技术领域的应用也日益增多，用于增强作物抗性和提高产量。主要市场的监管支持和有利政策也进一步促进了该行业的成长。学术机构和生技公司之间的合作也带来了新的机会，促进了创新并加速了基因静默技术的商业化。随着人们对精准医疗和个人化治疗的认识不断提高，基因静默市场预计将持续扩张。

限制与挑战：

基因静默市场面临许多重大限制与挑战。首先，基因静默技术高昂的研发成本对新参与企业构成重大障碍，并限制了现有企业的扩张。其次，监管障碍和严格的核准流程延缓了基因静默产品的商业化进程，影响了市场成长。第三，伦理问题和公众对基因修饰技术的担忧阻碍了其广泛应用。此外，基因静默机制的复杂性需要专业知识，导致熟练人才短缺，并增加了对培训和教育的需求。最后，技术的快速发展需要持续的创新和改进投入，这可能导致资源紧张，并减缓市场发展。这些挑战共同阻碍了基因静默解决方案的扩充性和广泛应用。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 短干扰RNA（siRNA）
    • 微型RNA（miRNA）
    • 短髮夹RNA（shRNA）
    • 反义寡核苷酸（ASO）
  • 市场规模及预测：依产品划分
    • 试剂
    • 装置
    • 成套工具
  • 市场规模及预测：依服务划分
    • 基因静默研究
    • 客製合成
    • 咨询
  • 市场规模及预测：依技术划分
    • RNA干扰（RNAi）
    • CRISPR-Cas9
    • 反义技术
  • 市场规模及预测：依应用领域划分
    • 药物发现与开发
    • 功能基因体学
    • 疾病诊断
    • 治疗药物
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 学术研究机构
    • 合约研究机构
  • 市场规模及预测：依组件划分
    • 向量
    • 转染试剂
    • 递送载体
  • 市场规模及预测：依製程划分
    • 体外
    • In vivo
  • 市场规模及预测：以作用方式划分
    • 直接的
    • 间接
  • 市场规模及预测：依发展阶段划分
    • 药物发现
    • 临床前阶段
    • 临床
    • 商业的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Silence Therapeutics
  • Dicerna Pharmaceuticals
  • Arcturus Therapeutics
  • Benitec Biopharma
  • Marina Biotech
  • Quark Pharmaceuticals
  • Sirnaomics
  • RXi Pharmaceuticals
  • Genevant Sciences
  • Calando Pharmaceuticals
  • Regulus Therapeutics
  • Gradalis
  • Atalanta Therapeutics
  • Stoke Therapeutics
  • Wave Life Sciences
  • ProQR Therapeutics
  • Bio-Path Holdings

第九章：关于我们

简介目录
Product Code: GIS33121

Gene Silencing Market is anticipated to expand from $4.66 billion in 2024 to $11.31 billion by 2034, growing at a CAGR of approximately 9.3%. The Gene Silencing Market encompasses technologies and methodologies aimed at suppressing gene expression, including RNA interference and antisense oligonucleotides. This market supports research and therapeutic applications, targeting genetic disorders and cancer. Innovations in delivery systems and specificity are pivotal, driven by the rising prevalence of genetic diseases and advancements in biotechnology. The demand for personalized medicine and novel treatments fuels growth, fostering partnerships between biotech firms and academic institutions.

The Gene Silencing Market is experiencing robust growth, fueled by advancements in genetic research and therapeutic applications. The RNA interference segment dominates, with small interfering RNA (siRNA) technologies leading due to their precision in gene targeting. Antisense oligonucleotides (ASOs) follow closely, driven by their versatility in modulating gene expression across various conditions. Within the RNA interference segment, the therapeutic application sub-segment is the top performer, as it offers promising treatments for genetic disorders and cancers. The research application sub-segment ranks second, supported by growing investments in genomic studies. The delivery technologies segment is also gaining momentum, with lipid nanoparticles being the preferred choice for their efficiency and safety in delivering gene silencing agents. Emerging innovations in delivery systems and expanding applications in personalized medicine further propel market growth. Strategic collaborations between biotech firms and research institutions enhance development pipelines, presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeShort Interfering RNA (siRNA), MicroRNA (miRNA), Short Hairpin RNA (shRNA), Antisense Oligonucleotides (ASO)
ProductReagents, Instruments, Kits
ServicesGene Silencing Research, Custom Synthesis, Consultation
TechnologyRNA Interference (RNAi), CRISPR-Cas9, Antisense Technology
ApplicationDrug Discovery and Development, Functional Genomics, Disease Diagnostics, Therapeutics
End UserPharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations
ComponentVectors, Transfection Reagents, Delivery Vehicles
ProcessIn Vitro, In Vivo
ModeDirect, Indirect
StageDiscovery, Preclinical, Clinical, Commercial

Market Snapshot:

The Gene Silencing Market is witnessing a dynamic shift with significant market share held by key industry players. Pricing strategies are increasingly competitive, reflecting the influx of new entrants and innovations. Recent product launches have introduced advanced gene silencing technologies, enhancing therapeutic applications and research capabilities. This is fostering a robust competitive environment, particularly in regions with substantial research funding and biotech investments. The market landscape is characterized by a continuous evolution of product offerings, driven by technological advancements and strategic collaborations. In terms of competition benchmarking, industry leaders are investing heavily in R&D to maintain their edge. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics. These regulations ensure safety and efficacy, impacting product approval timelines and market entry strategies. The competitive landscape is further influenced by patent laws and intellectual property rights, which are critical in sustaining innovation and protecting proprietary technologies. The market's trajectory is promising, with opportunities for growth in personalized medicine and RNA interference technologies.

Geographical Overview:

The gene silencing market is witnessing robust growth across various regions, each characterized by unique dynamics. North America leads, propelled by advanced research facilities and substantial investments in biotechnology. The region's focus on personalized medicine and genetic research further accelerates market expansion. Europe follows, with strong regulatory support and funding for genetic research fostering a thriving gene silencing ecosystem. The emphasis on innovation and collaboration among European nations enhances market potential. In Asia Pacific, rapid technological advancements and increasing healthcare expenditures drive significant market growth. Countries like China and India are emerging as key players, investing heavily in biotechnology and genomics. Latin America and the Middle East & Africa are nascent markets with growing opportunities. In Latin America, rising awareness and investments in genetic research are notable. Meanwhile, the Middle East & Africa are recognizing the potential of gene silencing in addressing region-specific health challenges, paving the way for future growth.

Key Trends and Drivers:

The gene silencing market is experiencing robust growth, propelled by advancements in genetic research and biotechnology. A key trend is the increasing application of RNA interference (RNAi) technology in therapeutic development, offering targeted treatment options for genetic disorders and chronic diseases. This trend is accelerated by the rising prevalence of such conditions globally. Another significant driver is the growing investment in research and development by pharmaceutical and biotechnology companies. These investments are aimed at discovering novel gene silencing techniques and expanding their therapeutic applications. Additionally, the expanding use of gene silencing in agricultural biotechnology to enhance crop resistance and productivity is noteworthy. Regulatory support and favorable policies in major markets are further bolstering the industry's growth. Opportunities are also arising from collaborations between academic institutions and biotech firms, fostering innovation and accelerating the commercialization of gene silencing technologies. As awareness of precision medicine and personalized therapies increases, the gene silencing market is poised for sustained expansion.

Restraints and Challenges:

The gene silencing market encounters several significant restraints and challenges. Firstly, the high cost of research and development in gene silencing technologies presents a substantial barrier to entry for new companies and limits the expansion of existing firms. Secondly, regulatory hurdles and stringent approval processes delay the commercialization of gene silencing products, impacting market growth. Thirdly, ethical concerns and public apprehension surrounding genetic modification technologies pose a challenge to widespread acceptance and adoption. Additionally, the complexity of gene silencing mechanisms requires specialized knowledge, limiting the pool of skilled professionals and increasing the demand for training and education. Finally, the rapid pace of technological advancement necessitates continuous investment in innovation and adaptation, which can strain resources and slow progress in the market. These challenges collectively impede the scalability and accessibility of gene silencing solutions.

Key Players:

Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Arcturus Therapeutics, Benitec Biopharma, Marina Biotech, Quark Pharmaceuticals, Sirnaomics, RXi Pharmaceuticals, Genevant Sciences, Calando Pharmaceuticals, Regulus Therapeutics, Gradalis, Atalanta Therapeutics, Stoke Therapeutics, Wave Life Sciences, ProQR Therapeutics, Bio-Path Holdings

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Mode
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Short Interfering RNA (siRNA)
    • 4.1.2 MicroRNA (miRNA)
    • 4.1.3 Short Hairpin RNA (shRNA)
    • 4.1.4 Antisense Oligonucleotides (ASO)
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Reagents
    • 4.2.2 Instruments
    • 4.2.3 Kits
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Gene Silencing Research
    • 4.3.2 Custom Synthesis
    • 4.3.3 Consultation
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 RNA Interference (RNAi)
    • 4.4.2 CRISPR-Cas9
    • 4.4.3 Antisense Technology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Drug Discovery and Development
    • 4.5.2 Functional Genomics
    • 4.5.3 Disease Diagnostics
    • 4.5.4 Therapeutics
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Academic and Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Vectors
    • 4.7.2 Transfection Reagents
    • 4.7.3 Delivery Vehicles
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 In Vitro
    • 4.8.2 In Vivo
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 Direct
    • 4.9.2 Indirect
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Discovery
    • 4.10.2 Preclinical
    • 4.10.3 Clinical
    • 4.10.4 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Process
      • 5.2.1.9 Mode
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Process
      • 5.2.2.9 Mode
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Process
      • 5.2.3.9 Mode
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Process
      • 5.3.1.9 Mode
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Process
      • 5.3.2.9 Mode
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Process
      • 5.3.3.9 Mode
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Process
      • 5.4.1.9 Mode
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Process
      • 5.4.2.9 Mode
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Process
      • 5.4.3.9 Mode
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Process
      • 5.4.4.9 Mode
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Process
      • 5.4.5.9 Mode
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Process
      • 5.4.6.9 Mode
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Process
      • 5.4.7.9 Mode
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Process
      • 5.5.1.9 Mode
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Process
      • 5.5.2.9 Mode
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Process
      • 5.5.3.9 Mode
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Process
      • 5.5.4.9 Mode
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Process
      • 5.5.5.9 Mode
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Process
      • 5.5.6.9 Mode
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Process
      • 5.6.1.9 Mode
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Process
      • 5.6.2.9 Mode
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Process
      • 5.6.3.9 Mode
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Process
      • 5.6.4.9 Mode
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Process
      • 5.6.5.9 Mode
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Alnylam Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Ionis Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Arrowhead Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Silence Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Dicerna Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Arcturus Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Benitec Biopharma
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Marina Biotech
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Quark Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Sirnaomics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 RXi Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genevant Sciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Calando Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Regulus Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Gradalis
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Atalanta Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Stoke Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Wave Life Sciences
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 ProQR Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Bio-Path Holdings
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us